nanotech-investing Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases 07 January
nanotech-investing Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors 22 October 2025
nanotech-investing Ventyx Biosciences to Participate in Three Upcoming Investor Conferences 27 August 2025
